A phase I study of a combination of yttrium-90- labeled anti-carcinoembryonic antigen(CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2935-2941

  Shibata, Stephen ^a,b   Raubitschek, Andrew ^a   Leong, Lucille ^a   Koczywas, Marianna ^a   Williams, Lawrence ^a   Zhan, Jiping ^a   Wong, Jeffrey Y C ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIBODY; CHIMERIC ANTIBODY; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMMUNOGLOBULIN G1; INDIUM 111; IRINOTECAN; PENTETIC ACID; YTTRIUM 90;

ADULT; ANTIBODY BLOOD LEVEL; APPENDIX CANCER; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; FEVER; FLUID RETENTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TESTIS CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; DEOXYCYTIDINE; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; TREATMENT OUTCOME;

EID: 65249121939     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2213     Document Type: Article

References (40)

1. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial ofyttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low- grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.J Clin Oncol2002;20:2453-63.
2. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
3. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial ofhigh-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclo- phosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non- Hodgkin lymphoma. Blood 2005;106:2896-902.
4. Jain M, Venkatraman G, Batra SK. Optimization of radio immunotherapy ofsolid tumors: biological impediments and their modulation. Clin Cancer Res 2007;13:1374-82.
5. Wong JY. Basic immunology of antibody targeted radiotherapy. Int J Radiat Oncol Biol Phys 2006;66: S8-14.
6. Wong JY, Shibata S, Williams LE, et al. A Phase I trial of90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842-52.
7. DeNardo SJ, Denardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006;66:S89-95.
8. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Radiosensitization by gemcitabine. Oncology (Huntingt) 1999;13:55-60.
9. Latz D, Fleckenstein K, Eble M, Blatter J, Wannen- macher M, Weber KJ. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′- deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998;41:875-82.
10. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-9.
11. Okazaki S,TM, Colcher D. Combination radio immunotherapy and chemotherapy using 131I-B72.3 and gemcitabine. Proceedings ofthe American Association for Cancer Research 39.1998.
12. Gold P, Schutsky K, CardilloTM. Successful treatment ofpancreatic cancer by combined gemcitabine and low dose radioimmunotherapy with 90Y-labeled PAM4 antibody. Proceeding of the American Association for Cancer Research 43. 2002.
13. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 2003;9:3712-21.
14. Nanfro JJ. Phase I trial dosing of gemcitabine and concurrentinvolved fieldirradiation in patients with localized pancreatic carcinomas. J Clin Oncol 1999;17: 3692.
15. Blackstock AW, Bernard SA, Richards F,et al. Phase I trial oftwice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-12.
16. Vokes EE, GregorA,Turrisi AT. Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol 1998;25:66-9.
17. Poplin EA, CorbettT, Flaherty L, et al. Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Invest New Drugs1992;10:165-70.
18. Wong JY,Thomas GE,Yamauchi D, et al. Clinical evaluation ofindium-111-labeled chimeric anti-CEAmono- clonal antibody. J Nucl Med 1997;38:1951 -9.
19. Wong JYC, Chu DZ, Yamauchi DM, et al. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6:3855-63.
20. Wong JY, Chu DZ, Williams LE, et al. A phase I trial of 90Y-DOTA-anti-CEA chimericT84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA- producing malignancies. Cancer Biother Radiopharm 2006;21:88-100.
21. Odom-Maryon TL, Williams LE, Chai A, et al. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans. J Nucl Med 1997;38:1959-66.
22. Loevinger R. BM. A schema for absorbed-dose calculations for biologically-distributed radionuclides. J Nucl Med 1968;9:7-14. J Nucl Med 1968;MIRD pamphlet no.1 (9 Suppl 1):7-14.
23. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-46.
24. Williams LE, Primus FJ,WongJYC,et al. Biodistribution ofan In-111 orY-90 labeled chimeric anti-CEA monoclonal antibody (cT84.66) following its large scale production in a bioreactor.TumorTargeting1996;2:116-24.
25. Siegel JA,Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213-33.
26. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;03:253-5.
27. Loevinger R, Japha EM, Brownell GL. Discrete radioisotope sources. In: Hine GJ, Brownell GL, editors. Radiation Dosimetry, 732-739. New York: Academic Press; 1956. p. 732-9.
28. Loevinger R. Japha, EM, Brownell, GL. Internally administered radioisotopes. In: Hine GJ, Brownell GL, editors. Radiation Dosimetry. Academic Press New York 1956.1956. p. 824.
29. Green MR. Gemcitabine safety overview. Semin Oncol 1996;23:32-5.
30. Jeter MD, Janne PA, Brooks S, et al. Gemcitabine induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400.
31. Chong G, Lee FT, Hopkins W, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 2005;11:4818-26.
32. Jacobs AJ, Fer M, Su FM, et al. A phase I trial ofa rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 1993;82: 586-93.
33. Wang WS,Lin JK,LinTC,et al. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer. Hepatogastroenterology 2002;49:388-92.
34. Hanke B, RiedelC,Lampert S, et al.CEA and CA 19-9 measurement asa monitoringparameterin metastatic colorectal cancer (CRC) under palliative first line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinicacid (FA). Ann Oncol 2001;12:221 -6.
35. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 2006;70:49-53.
36. Sorbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 2004;43:495 -8.
37. Louagie H,Van EM, Philippe J, Thierens H, de RL. Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int J Radiat Biol 1999;75:767 -71.
38. Bachtiary B, Herbacek I, ZideckT, et al. Impact of radiotherapy with and without concurrent cisplatin on lymphocyte subpopulations in cervical cancer patients. Anticancer Res 2005;25:4673 -8.
39. Wong JY. Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys 2006;66:S74-82.
40. Meredith RF, Wong JYC, Knox SJ. Radioimmunotherapy. In: Gunderson LG,TepperJE, editors. Clinical Radiation Oncology. Philadelphia: 2006.